CTI Announces Formation of Korean Subsidiary and Opening of Seoul Office

“The expansion into Korea is part of efforts to increase capacity for clinical research in one of Asia’s fastest-growing countries for drug development,” according to Patrick Earley, Vice President, International. “We have been working with leading Korean academic medical centers for a number of years, as well as collaborating with innovative Korean biotechnology companies. This expansion will only further enhance the relationships and collaborations we have in the country.”

CTI Named Top Workplace

CTI is named a Top Workplace in Cincinnati and CEO, Tim Schroeder, is recognized as ‘Best in Show’ for Leadership.

CTI Announces Complete Enrollment of Galectin Therapeutics Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis

“We are very pleased to partner with Galectin on this novel study in NASH, which affects millions of people around the world, and are excited the trial has reached this pivotal milestone,” according to Joseph McCafferty, Vice President, Global Business Development & Client Management. 

CTI Clinical Research Associates Are "Critical In The Success That We Have Had In Our Study"

Global clinical monitoring coverage for CTI, is built around the philosophy of providing therapeutic expertise to our sponsors. CTI Clinical Research Associates (CRAs) have significant experience working with complex studies and critically ill patients. Our staff has decades of experience in research and nursing outside of their CRA experience. With an average retention rate of over 95%, our CRAs are able to see their studies through from start‐up to close‐out.

CTI Collaborates With Vtesse on Novel Phase 2b/3 Clinical Trial for Treatment of Niemann-Pick Type C1 (NPC) Disease

“We’re thrilled to be partners with Vtesse and the entire NPC community in this effort to develop a drug that may be approved to treat this devastating disease,” according to Timothy J. Schroeder, CTI Chief Executive Officer. 

CTI Collaborated With Tuberous Sclerosis Alliance To Analyze Natural History Database

“We’re finding that groups like the Tuberous Sclerosis Alliance are becoming increasingly more important in drug development and research in rare diseases, as there is often a lack of information on rare disorders in published literature or traditional databases,” according to Joseph McCafferty, Vice President, North American Sales. 

3 out of 4 Sites around the World Prefer CTI to Other CROs

CTI announced the results of the independently commissioned site survey that was sent out earlier this year. Overall, three out of four sites prefer CTI over all other CROs, and nearly 95% of respondents view CTI as equal to or better than other CROs that they have recently worked with.


Rare Disease / Orphan Disease

CTI is a leader in rare disease and orphan disease research with approximately 80% of our work falling into this category.

Learn More


CTI is a leader in this field with contributions to nearly all transplant-related therapies on the market today.

Learn More

Safety & Pharmacovigilance

CTI’s global Safety and Pharmacovigilance team has broad experience with a variety of databases and technology, in addition to concentrated experience with critically ill patients.

Learn More

Participate in a Trial

Icon Careers Small Retina

CTI CRC is looking for volunteers to participate in our current trials. 

Learn More

Join our Team

Icon Briefcase Small Retina

At CTI, our employees are offered the opportunity to make a difference for themselves, their families, and in the medical community in which we work.

Learn More

Latest News

CTI Named Top Workplace

June 16, 2016